Researchers have developed a tiny microfluidic device capable of incubating cancer cells for long enough to investigate the intricate details of metastatic characteristics.
A novel handheld device has been designed that could enable fast and accurate diagnosis in oncological surgeries, utilizing mass spectrometry technology.
A DNA methylation biomarker (POU4F3) and quantitative assay may provide a two-pronged approach to improve the preclinical identification and diagnosis of cervical cancers.
A new body-on-a-chip device could be a cheaper and safer step in the preclinical testing of drugs developed for cancer.
Researchers have developed a test that could detect a biomarker for liver cancer, alpha-fetoprotein.
Novel technology, using single-color digital PCR, could enable the detection of cancerous DNA in circulating blood.
Researchers have identified a panel of biomarkers in serum samples that could accurately detect the early stages of pancreatic cancer.
The start-up company, Inlighta Biosciences LLC (GA, USA), have received a $2 million federal grant for the development of an improved MRI contrast agent that could be utilized for early detection of liver cancer.
Researchers have developed an innovative technique to detect tumor DNA in blood with a greater degree of sensitivity and precision.
Biosimilar trastuzumab candidate (CT-P6) shown to be similar in efficacy and safety to the reference trastuzumab in data presented at the 2017 American Society of Clinical Oncology Annual Meeting (IN, USA).